Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12439243 | 0.86 | CA12 (0.47) | CA12CA14CA1CA7ADRB2 | |
| SCHEMBL12439239 | 0.86 | CA12 (0.55) | CA12CA14CA1CA7ADRB2 | |
| SCHEMBL2439786 | 0.82 | ADRB2 (0.58) | ADRB2ADRB1CYP2D6NFKB1HIF1A | |
| SCHEMBL12439242 | 0.79 | CA12 (0.50) | CA12CA14CA1CA7ADRB2 | |
| SCHEMBL12438380 | 0.79 | CA12 (0.50) | CA12CA14CA1CA7CA2 | |
| SCHEMBL13997815 | 0.75 | ADRB2 (0.49) | ADRB2ADRB1CYP2D6NFKB1HIF1A | |
| SCHEMBL14148346 | 0.75 | CA12 (0.50) | CA12CA14CA1CA7CA2 | |
| SCHEMBL12438383 | 0.75 | CA12 (0.56) | CA12CA14CA1CA7CA2 | |
| SCHEMBL14148327 | 0.74 | CA12 (0.50) | CA12CA14CA1CA7CA2 | |
| SCHEMBL10217111 | 0.74 | CA12 (0.41) | CA12CA14CA1CA7ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302546-A1 | NOVEL SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND METHODS FOR USE THEREOF | FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| WO-2011097337-A1 | NOVEL SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND METHODS FOR USE THEREOF | ADVANCED NEURAL DYNAMICS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302546-A1 | NOVEL SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND METHODS FOR USE THEREOF | GRIK2, GRIK5, GRIN2A | CA12 750/4885CA14 1699/4885CA1 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.